Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Creative Biogene is committed to providing high quality products and services to help scientists around the world find solutions in biological research and drug discovery.
Cancer immunotherapy can reverse tumor immune escape by suppressing immune checkpoint pathways. It is possible that the inhibition of pathway checkpoints, including CTLA4, PD1 and PDL1, could activate T cells to attack and eliminate cancer.
The potential of T cells to attack and destroy tumors has long been recognized. Recent experimental evidence has also demonstrated that T cell surveillance throughout the life of an organism functions to prevent tumor development.
Immunotherapy is an emerging alternative or adjunct to traditional cancer therapies, its goal being to stimulate a potent and specific anti-tumor immune response. The agonistic anti-CD40 monoclonal antibody is one of the most promising immunotherapies tried so far in animal models.
Tumor cells can escape the immune surveillance and disrupt immune checkpoint of host in several methods, therefore, to avoid the elimination from the host immune system. Numerous pathways are utilized by cancers to up-regulate the negative signals through cell surface molecules.
Chronic pain affects a large segment of the population, an estimated 50 million Americans, and costs the country billions of dollars in health care costs and lost productivity. Although the Decade of Pain Control and Research has given new impetus to pain research, the translation of preclinical research into clinical practice is slow to occur.
Copyright © 2026 Creative Biogene. All rights reserved.